Reduced C–Terminal Src Kinase (Csk) Activities in Hepatocellular Carcinoma

Open Access
Publisher Website
Google Scholar
Abstract
The proto–oncogene product pp60c–src is the cellular homologue of the Rous sarcoma transforming gene, and it is a non-receptor–linked and membrane–associated tyrosine kinase. There is a close correlation between elevated pp60c–src activity and cell transformation. We have recently reported that pp60c–src was activated in hepatocellular carcinoma (HCC) of human and Long–Evans cinnamon (LEC) rats. However, the mechanisms involved in this process remain unknown. C–terminal Src kinase (Csk) is a novel cytoplasmic protein tyrosine kinase that inactivates the members of the Src family protein tyrosine kinase in vitro. We investigated the role of Csk in hepatocarcinogenesis by analyzing the location, amount of Csk, and its kinase activity levels in nontumorous cirrhotic and tumorous sections of HCC of patients and an animal model of LEC rats. Csk tyrosine kinase activity was significantly reduced in tumorous tissues compared with nontumorous sections of patients as well as LEC rats. A single immunoreactive band at 50 kd was detected with Csk antibody in normal liver (NL), chronic hepatitis (CH), and nontumorous cirrhotic (NTC) segments of HCC of patients and LEC rats. In human tumorous tissues, Western blot revealed a 53–kd immunoreactive band, which was slightly larger than the usual 50–kd band of Csk. These results suggest that the reduced activity of tyrosine kinase of Csk may play an important role in the malignant transformation of hepatocytes in human and LEC rat, and the appearance of 53–kd Csk–related protein may be closely involved in the progression of cirrhosis to HCC in humans, and that 50–kd Csk may act as an antioncogene through the negative regulation of pp60c–src in the development of human HCC